# OnCo record male-breast-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/male-breast-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "male-breast-cancer" ;
  schema:name "Male breast cancer"@en ;
  schema:alternateName "Breast cancer in men"@en ;
  schema:description "Men get breast cancer too, usually a hormone-sensitive kind found as a lump near the nipple. It is treated much as in women, with surgery, radiotherapy and tamoxifen, and inherited BRCA2 mutations are found often enough that every man diagnosed is offered genetic testing. The main fix under way is including men in trials so their care stops being borrowed from women."@en ;
  schema:url <https://onco.cc/cancers/male-breast-cancer/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Male_breast_cancer> ;
  schema:citation <https://www.cancer.gov/types/breast/male-breast-cancer>, <https://doi.org/10.1200/JCO.19.03120>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/male-breast-cancer-developing-drugs-treatment>, <https://doi.org/10.1093/annonc/mdx651> ;
  onco:tag "nci-coverage", "rare", "breast" ;
  onco:related <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/ductal-carcinoma-in-situ/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/mammography/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/goserelin/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:pathways <https://onco.cc/pathways/er-signaling/>, <https://onco.cc/pathways/homologous-recombination-repair/> ;
  onco:terms <https://onco.cc/terms/hormone-receptor-status/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/terms/hereditary-cancer-syndromes/> ;
  onco:trials <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/nct04842617/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-trial-diversity/>, <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-cardoso-ann-oncol/>, <https://onco.cc/key-papers/paper-hassett-j-clin-oncol/> ;
  onco:pipeline <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:standardOfCare <https://onco.cc/terms/mastectomy/>, <https://onco.cc/technologies/sentinel-node/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/goserelin/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/fulvestrant/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/trials/olympia/> .